December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tonix Pharmaceuticals Holding Corp. - Common Stock (NQ:TNXP)

14.35 -0.49 (-3.32%)
Streaming Delayed Price Updated: 3:38 PM EST, Feb 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tonix Pharmaceuticals Holding Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in March Investor Conferences
Via Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Phase 3 Data for TONMYA(TM) in Fibromyalgia at Non-Opioid Pain Summit
Via Investor Brand Network
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at January Investor Conferences
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at January Investor Conferences
Via Investor Brand Network
This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’ ↗
Via Stocktwits
Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail’s Optimistic ↗
Via Stocktwits
News headline image
Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug ↗
The company also announced the pricing of a $20 million registered direct offering. 
Via Stocktwits
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Provides Update on TNX-4800 Lyme Disease Prophylaxis Program
Via Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Announces $20 Million Registered Direct Offering with Point72
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Appoints Irina Ishak as General Counsel
Via Investor Brand Network
News headline image
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
From BioMedWire
Via GlobeNewswire
News headline image
Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’ ↗
Retail traders pointed to the expanded buyback authorization as a sign of management confidence, framing it as a potential catalyst for renewed valuation upside. 
Via Stocktwits
News headline image
Why Did TNXP Stock Jump 10% Today? ↗
Tonix Pharmaceuticals on Monday announced the launch of its new drug to treat Fibromyalgia. 
Via Stocktwits
News headline image
Why Tonix Pharmaceuticals (TNXP) Stock Jumped Monday Morning ↗
Tonix Pharmaceuticals shares are rising Monday morning after the company announced the U.S. commercial availability of its new drug, TONMYA. 
Via Benzinga
News headline image
TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) Surges 77% on Q3 Earnings Beat and Key Drug Launch ↗
Tonix Pharmaceuticals stock surged 77% after Q3 earnings beat estimates and confirming the November launch of its new fibromyalgia drug, Tonmya. 
Via Chartmill
Topics Earnings
News headline image
Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern
San Diego, CA – November 10, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a dramatic collapse in its stock price, shedding nearly 50% of its value following the announcement of mixed results... 
Via MarketMinute
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances TNX-2900 for Prader-Willi Syndrome Into Phase 2 Trial
Via Investor Brand Network
News headline image
Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
What's going on in today's session ↗
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Monday's session: top gainers and losers ↗
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years ↗
FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025. 
Via Benzinga
News headline image
Why Dayforce Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Wondering what's happening in today's after-hours session? ↗
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
Why KULR Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
What's Going On With Tonix Pharmaceuticals (TNXP) Stock? ↗
Shares of Tonix Pharmaceuticals have rallied 30% over the past five sessions. Investors are anticipating a key catalyst for the company. 
Via Benzinga
News headline image
Why Tonix Pharmaceuticals (TNXP) Stock Is Climbing This Week ↗
Shares of Tonix Pharmaceuticals are building on recent gains. The stock is trading higher as investor focus intensifies on a key, upcoming catalyst. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.